Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease.
During a double blind, inpatient-outpatient study of THA (tacrine) and lecithin in Alzheimer's disease, data on a laboratory-based delayed-matching-to-sample (DMS) test was collected on six of 10 subjects. DMS measures proved more sensitive to drug effects than clinical measures of cognitive performance. Both clinical and DMS measures suggest that patients with mild to moderate impairment are more likely to show modest improvement in performance than advanced cases. Outcome measures are related to possible mechanisms of attention and memory.
Perryman
K M
KM
Department of Psychiatry, UCLA School of Medicine.
Fitten
L J
LJ
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology*; D000704:Analysis of Variance; D003071:Cognition / Q000187:drug effects*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D011597:Psychomotor Performance / Q000187:drug effects; D013619:Tacrine / Q000627:therapeutic use*
D010713:Phosphatidylcholines; D013619:Tacrine